Leerink upgraded Johnson & Johnson to Outperform from Market Perform with a price target of $265, up from $252. The firm says the company’s “strong new drug momentum” will drive accelerating revenue growth and share outperformance. Leerink upped its estimates for Icotyde and Inlexzo and believes J&J at its December 8 analyst day will “provide more justification for its aspiration” to deliver double-digit revenue growth late in the decade.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Stereotaxis price target lowered to $3.50 from $4 at Piper Sandler
- Johnson & Johnson upgraded to Outperform from Market Perform at Leerink
- FDA Commissioner Marty Makary resigns
- Trump confirms Kyle Diamantas to be acting head of FDA
- Trump Trade: Trump to suspend tariff-rate quotas on beef imports